A detailed history of Adalta Capital Management LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Adalta Capital Management LLC holds 18,877 shares of BMY stock, worth $1.03 Million. This represents 0.47% of its overall portfolio holdings.

Number of Shares
18,877
Previous 18,877 -0.0%
Holding current value
$1.03 Million
Previous $1.02 Million 23.46%
% of portfolio
0.47%
Previous 0.62%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$47.98 - $54.4 $2,399 - $2,720
-50 Reduced 0.26%
18,877 $1.02 Million
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $7,999 - $9,545
-165 Reduced 0.86%
18,927 $971,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $7,815 - $8,738
-135 Reduced 0.7%
19,092 $1.11 Million
Q2 2023

Aug 23, 2023

SELL
$63.71 - $70.74 $4,523 - $5,022
-71 Reduced 0.37%
19,227 $1.23 Million
Q1 2021

May 18, 2021

BUY
$59.34 - $66.74 $14,835 - $16,685
250 Added 1.31%
19,298 $1.23 Million
Q3 2020

Nov 17, 2020

SELL
$57.43 - $63.64 $2,871 - $3,182
-50 Reduced 0.26%
19,048 $1.15 Million
Q1 2020

May 18, 2020

SELL
$46.4 - $67.43 $46,400 - $67,430
-1,000 Reduced 4.98%
19,098 $1.06 Million
Q4 2019

Feb 14, 2020

SELL
$49.21 - $64.19 $8,611 - $11,233
-175 Reduced 0.86%
20,098 $1.29 Million
Q4 2018

Feb 15, 2019

SELL
$48.76 - $63.23 $13,409 - $17,388
-275 Reduced 1.34%
20,273 $1.05 Million
Q2 2018

Aug 15, 2018

SELL
$50.53 - $62.98 $30,318 - $37,788
-600 Reduced 2.84%
20,548 $1.14 Million
Q4 2017

Feb 14, 2018

SELL
$59.94 - $65.35 $41,058 - $44,764
-685 Reduced 3.14%
21,148 $1.3 Million
Q3 2017

Nov 24, 2017

BUY
$55.23 - $63.74 $1.21 Million - $1.39 Million
21,833
21,833 $1.39 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Adalta Capital Management LLC Portfolio

Follow Adalta Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Adalta Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Adalta Capital Management LLC with notifications on news.